These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical usefulness of serum procollagen-III-peptide in patients with solid tumor].
    Author: Takahashi T, Takami H, Abe O, Ootake T, Kano S.
    Journal: Gan To Kagaku Ryoho; 1984 Jul; 11(7):1480-6. PubMed ID: 6204598.
    Abstract:
    An attempt has been made to determine the clinical usefulness of serum procollagen-III-peptide (P-III-P) in comparison with serum CEA and AFP in patients with solid tumor. Serum P-III-P levels were measured in 82 cases of carcinoma and 64 cases of benign disease employing an AG Radiochemishes Laboratrium RIAgnost P-III-P kit. Serum P-III-P levels of 148 healthy subjects were 8.5 +/- 2.6 ng/ml (M +/- S.D.), with an upper limit of 13.7(M + 2S.D.). The serum P-III-P level in cases of hepatocellular carcinoma was elevated to 47.5 +/- 97.5 (88.9%). Serum P-III-P levels in cases of pancreatic carcinoma were elevated slightly, whereas those for patients with carcinoma of the stomach, colorectum, esophagus, and breast were low, and their P-III-P positive rates were lower than those of their serum CEA. On the other hand, the serum P-III-P levels in benign diseases involving the liver and biliary tract were higher than those in other benign diseases. Therefore, although serum P-III-P can be a useful marker in hepatocellular carcinoma, it may possibly be difficult to discriminate it from benign diseases involving the liver and biliary tract.
    [Abstract] [Full Text] [Related] [New Search]